A detailed history of Bank Of America Corp transactions in Medicinova Inc stock. As of the latest transaction made, Bank Of America Corp holds 76,349 shares of MNOV stock, worth $156,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,349
Previous 118,661 35.66%
Holding current value
$156,515
Previous $170,000 5.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.13 - $2.1 $47,812 - $88,855
-42,312 Reduced 35.66%
76,349 $160,000
Q2 2024

Aug 14, 2024

SELL
$1.28 - $1.57 $38,141 - $46,782
-29,798 Reduced 20.07%
118,661 $170,000
Q1 2024

May 15, 2024

SELL
$1.28 - $1.65 $24,960 - $32,175
-19,500 Reduced 11.61%
148,459 $215,000
Q4 2023

Feb 14, 2024

BUY
$1.38 - $2.06 $82,110 - $122,570
59,500 Added 54.86%
167,959 $251,000
Q2 2023

Aug 14, 2023

SELL
$2.09 - $2.43 $54,130 - $62,937
-25,900 Reduced 19.28%
108,459 $249,000
Q1 2023

May 12, 2023

SELL
$1.95 - $2.54 $83,655 - $108,966
-42,900 Reduced 24.2%
134,359 $290,000
Q4 2022

Feb 10, 2023

BUY
$1.97 - $2.66 $44,340 - $59,871
22,508 Added 14.54%
177,259 $363,000
Q3 2022

Nov 14, 2022

SELL
$2.1 - $2.6 $9,870 - $12,220
-4,700 Reduced 2.95%
154,751 $336,000
Q2 2022

Aug 12, 2022

SELL
$2.31 - $3.14 $46,260 - $62,881
-20,026 Reduced 11.16%
159,451 $403,000
Q1 2022

May 16, 2022

SELL
$2.19 - $2.81 $70,257 - $90,147
-32,081 Reduced 15.16%
179,477 $480,000
Q4 2021

Feb 08, 2022

BUY
$2.61 - $4.42 $175,167 - $296,643
67,114 Added 46.46%
211,558 $567,000
Q3 2021

Nov 15, 2021

SELL
$3.4 - $4.24 $82,684 - $103,112
-24,319 Reduced 14.41%
144,444 $548,000
Q2 2021

Sep 13, 2021

BUY
$3.76 - $5.14 $634,548 - $867,441
168,763 New
168,763 $717,000

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $101M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.